Cost-Utility Analysis (CUA) of Belimumab (BEL) in the Treatment of Adult Patients with Active, Autoantibody-Positive Systemic Lupus Erythematosus (SLE)
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.359
https://www.valueinhealthjournal.com/article/S1098-3015(13)02264-X/fulltext
Title :
Cost-Utility Analysis (CUA) of Belimumab (BEL) in the Treatment of Adult Patients with Active, Autoantibody-Positive Systemic Lupus Erythematosus (SLE)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02264-X&doi=10.1016/j.jval.2013.08.359
First page :
A385
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
344